Zebularine/PPD combinational therapy downregulates the level of TGF‐β and PD‐L1, reduces the proportion of pro‐tumour immune cells (M2, Tregs and MDSCs), suppresses tumour growth and relapse, and prevents metastasis.1 The gene discussed is CD274; the disease is neoplasm.